Strikingly, our results indicated that co-treatment with HK2 inhibitor and doxorubicin significantly inhibited the growth of subcutaneous lung (i.e. LLC, A549) or liver (i.e. mouse HCC cell line Hepa 1-6) tumors as compared to the group treated with either placebo, doxorubicin, or HK2 inhibitor alone (Fig. 6a–d and Supplementary fig. 8a–h). Here, HK2 is linked to hepatocellular carcinoma.